Assembly Biosciences (ASMB) Shares Up 5.7%

Assembly Biosciences Inc (NASDAQ:ASMB)’s share price shot up 5.7% during trading on Friday . The stock traded as high as $21.25 and last traded at $21.09. 558,462 shares changed hands during trading, an increase of 73% from the average session volume of 323,183 shares. The stock had previously closed at $19.96.

Several research firms recently commented on ASMB. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a research report on Sunday, October 28th. Zacks Investment Research upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 1st. Leerink Swann began coverage on Assembly Biosciences in a research report on Monday, November 19th. They set an “outperform” rating and a $45.00 target price for the company. Finally, B. Riley upgraded Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Monday, October 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $52.00.

The stock has a market capitalization of $560.19 million, a P/E ratio of -8.34 and a beta of 1.42.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.14. Assembly Biosciences had a negative return on equity of 50.63% and a negative net margin of 469.91%. The firm had revenue of $4.29 million during the quarter, compared to analysts’ expectations of $3.21 million. Sell-side analysts anticipate that Assembly Biosciences Inc will post -4 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of ASMB. Legal & General Group Plc boosted its holdings in shares of Assembly Biosciences by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 3,289 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 616 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth about $282,000. Point72 Asset Management L.P. purchased a new position in shares of Assembly Biosciences in the 3rd quarter worth about $407,000. American International Group Inc. boosted its holdings in shares of Assembly Biosciences by 26.1% in the 3rd quarter. American International Group Inc. now owns 13,946 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 2,886 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new position in shares of Assembly Biosciences in the 3rd quarter worth about $540,000. Hedge funds and other institutional investors own 84.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2019/01/12/assembly-biosciences-asmb-shares-up-5-7.html.

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Further Reading: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply